ITMCTR2000003847招募中1 期
Treatment of severe immune thrombocytopenia with hormone resistance by combination of traditional Chinese and Western Medicine
Shanghai Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 性别
- All
入选标准
- •(1) Aged 18-80 years old male and female;
- •(2) Patients with ITP who were treated with glucocorticoid for more than 4 weeks met the diagnostic standard of Chinese expert consensus on diagnosis and treatment of adult primary immune thrombocytopenia (Revised Edition) (2018), and TCM syndrome differentiation belongs to Qi and yin deficiency type;
- •(3) Two consecutive platelet tests (not detected in the same day) <= 20 x 10^9/L;
- •(4) Those who voluntarily sign informed consent.
排除标准
- •(1) Although it meets the diagnostic criteria of Western medicine, TCM syndrome is not Yin deficiency type;
- •(2) Patients with history of thrombosis;
- •(3) HBV, HCV, HIV carriers or patients;
- •(4) Allergic constitution or allergic to a variety of drugs;
- •(5) Pregnant or lactating women;
- •(6) Patients with a history of mental illness;
- •(7) Suspected or confirmed history of alcohol and drug abuse;
- •(8) Severe abnormal function of heart, lung, liver and kidney;
- •(9) Severe or uncontrollable infection;
- •(10) Those who took other traditional Chinese medicine or participated in other clinical trials in recent 4 weeks;
- •(11) Any other circumstances in which the investigator believes that the patient should not participate in this study.
研究者
相似试验
未知
3 期
Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective ProcedureThrombocytopenia Associated With Chronic Liver DiseaseJPRN-jRCT2080222694Eisai Co., Ltd.300
已完成
不适用
Chronic disease in Immune Thrombocytopenia of Childhoodplatelet destruction by antibodies1003553410003816immune thrombocytopenic purpuraNL-OMON36447niversitair Medisch Centrum Utrecht60
进行中(未招募)
不适用
Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes.Adult subjects (18 yearsof age or older) with lowor intermediate-1 IPSSrisk MDS andthrombocytopeniaMedDRA version: 18.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2010-022890-33-FRASSOCIAZIONE QOL-ONE171
进行中(未招募)
1 期
Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes.EUCTR2010-022890-33-SIASSOCIAZIONE QOL-ONE174
招募中
2 期
Eltrombopag for the treatment of thrombocytopenia due to low - and intermediate risk myelodysplastic syndromes.2024-520133-72-00Associazione Qol-One160
